Bulevirtide is a medicine for chronic hepatitis D, a serious liver infection. It blocks the doorway the virus uses to get into liver cells, so the virus can't spread as easily. It is given as a shot under the skin.
Every report comes from a Lived member, sent anonymously.
Have you tried Hepcludex (Bulevirtide) for Chronic Hepatitis D?
Bulevirtide, sold as Hepcludex, is a prescription antiviral injection for chronic hepatitis D in adults. It is approved for people whose liver either has not developed cirrhosis (severe scarring) or has cirrhosis that is still compensated, meaning the liver is still managing its main jobs. On US pharmacy labels the generic name may appear as bulevirtide-gmod. The hepatitis D virus (HDV) can only infect people who already have hepatitis B, because it needs parts of the hepatitis B virus to multiply. Having both infections usually causes a more aggressive liver disease than hepatitis B alone, with faster progression to cirrhosis. The US approval is an accelerated approval. It was granted because bulevirtide lowered the amount of hepatitis D virus in the blood and brought liver enzyme levels back to normal in many people. It has not yet been shown to prevent cirrhosis complications, liver cancer or death, and further studies are required to confirm those longer-term benefits.
To infect a liver cell, the hepatitis D virus first has to latch onto a protein on the cell's surface called NTCP (sodium taurocholate co-transporting polypeptide). Bulevirtide is a lab-made protein fragment modeled on part of the hepatitis B virus's outer coat. It binds to NTCP itself, so the virus cannot attach and enter new liver cells. With fewer new cells being infected, the amount of virus in the blood can fall and liver inflammation can settle. NTCP's normal job is to pull bile salts from the blood into the liver. Because bulevirtide occupies it, bile salt levels in the blood rise during treatment; this is expected and reverses when treatment stops. Bulevirtide acts on hepatitis D, not on hepatitis B, so it does not replace hepatitis B care.
Hepcludex comes as a powder in a single-dose vial containing 8.5 mg. Once a day, the powder is mixed with 1 mL of sterile water and injected under the skin of the upper thigh or lower abdomen; a caregiver can also inject into the back of the upper arm. The mixed solution is used right away and never saved for later. The sterile water, syringes and needles are supplied separately by the pharmacy, and unopened vials are kept at room temperature. A clinician trains the person or a caregiver to prepare and give the injection, and the first dose may be given under supervision. Taking it on a regular daily schedule matters. If a dose is missed, take it as soon as possible, unless the next dose is nearly due; in that case skip the missed dose and continue the usual schedule. The underlying hepatitis B infection is still managed on its own terms, so hepatitis B medicines are continued or started as the care team decides.
The most common side effects in the main trial were reactions where the injection goes in (such as redness, itching, swelling, bruising or pain, in about 3 in 10 people), headache, abdominal pain, tiredness and itchy skin. No one in that trial stopped treatment because of side effects during the first year. Blood tests show raised bile salts in everyone taking bulevirtide, as a direct result of how it works, and the levels return to normal after stopping. About 1 in 7 people in the trial had itching, which was mild to moderate and settled on its own; how high the bile salts rose did not predict who itched. Serious allergic reactions, including anaphylaxis, have been reported since the medicine came into use. Trouble breathing, swelling of the face, lips or throat, or widespread hives after an injection need emergency care right away (call 911), and no further doses should be given until the care team has been told.
The most important warning concerns stopping. When bulevirtide is stopped, hepatitis D and hepatitis B can flare up severely. In people with cirrhosis, a flare can lead to decompensation, a serious loss of liver function. For that reason, treatment should be stopped only after talking with the care team, and liver blood tests, including hepatitis B and hepatitis D virus levels, continue closely for at least six months afterward. Restarting antiviral treatment may be needed. Few drug interactions are expected. Bulevirtide is broken down the way other proteins are, rather than by the liver enzymes that process many pills, and it is not expected to change how other medicines are handled. The care team and pharmacist should still have a full list of medicines and supplements. Bulevirtide has not been studied in people with moderate or severe liver impairment, in people with end-stage kidney disease, or in children under 18. Human data in pregnancy are too limited to judge the risk, although animal studies found no harm to the developing fetus, and it is not known whether it passes into breast milk. Anyone pregnant, planning a pregnancy or breastfeeding should weigh treatment with the specialist, alongside the risks of untreated hepatitis D.
Bulevirtide is an ongoing daily treatment, not a short course; the main trial followed people for nearly three years of treatment. Progress is tracked with blood tests: HDV RNA, which counts the virus's genetic material (ribonucleic acid) to show how much hepatitis D virus is in the blood, and ALT (alanine aminotransferase), a liver enzyme that rises when the liver is inflamed. In the main trial, a good response meant HDV RNA becoming undetectable or falling at least 100-fold, together with a normal ALT. After 48 weeks, 48% of people on bulevirtide reached that, compared with 2% of people who had not yet started treatment. With continued treatment, the share whose virus was undetectable rose from 20% at 48 weeks to 50% at nearly three years. Not everyone responds, and the best length of treatment is unknown; the label advises continuing for as long as the medicine is still working. Responses often fade after stopping. In the trial, about a quarter of participants still had a good response nearly two years after treatment ended. Regular specialist follow-up for hepatitis B and, where present, cirrhosis continues alongside treatment.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Hepcludex (Bulevirtide), what you've noticed, or ask the community a question.